Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyProvidence genetic panel coverage & prior auth | O…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy 213

    Non-Covered Genetic Panel Tests

    Customize your policy alerts

    Sign up for Providence Health Plan Policy 213 alerts

    Get alerted when Policy 213 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines genetic panel tests considered not medically necessary by Providence Health Plan and the documentation/prior authorization expectations for providers requesting genetic panel testing for Commercial plan members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerProvidence Health Plan
    PolicyNon-Covered Genetic Panel Tests
    Policy CodePolicy 213
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateSep 1, 2026
    Key ActionProvide clinical documentation with prior authorization including panel or gene list, performing laboratory, clinical rationale, supporting findings, family history when applicable, and CPT codes billed.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    213Policy ID
    Commercial onlyPlan Applicability
    Many listedNon-covered panels
    YesDocumentation required

    Coverage criteria and policy scope

    Not Medically Necessary (Insufficient Clinical Utility)

    Not medically necessary when clinical utility is insufficient; both A and B must be met for each gene/component:

    Main criteria: Genetic panel testing is considered not medically necessary when there is insufficient evidence that the panel has proven clinical utility. To establish clinical utility, both of the following criteria (A. and B.) must be met for each gene and/or component of the panel test:
    A: Testing allows for a definitive diagnosis or risk classification AND either (1) other clinical and/or laboratory tests were inconclusive OR (2) testing avoids a more invasive diagnostic test (e.g., muscle biopsy).
    B: Test results will guide decisions in clinical management (predictive, diagnostic, prognostic, or therapeutic).

    Non-covered panels due to insufficient clinical utility

    Not covered when the following applies

    Panels lacking proven clinical utility: Genetic panels or panel components for which there is insufficient evidence that all genes/components provide actionable risk, diagnostic, or prognostic information that impacts medical management and improves health outcomes are considered not covered.

    Laboratory-performed tests must be FDA-approved and/or performed in a CLIA-accredited laboratory and scientifically validated for the requested indication; FDA approval alone does not establish medical necessity.

    This policy excludes certain test types from its scope. It does not address whole exome or whole genome sequencing, nor does it address genetic tests related to reproductive planning or prenatal testing. The list of non-covered panels in this policy is illustrative and not exhaustive, and panel names, gene content, and coding may change over time. When available, condition- or test-specific medical policies should be applied instead of this general non-coverage list.

    Laboratories performing genetic panel tests must meet regulatory and validation expectations. Tests should be performed in a CLIA‑accredited laboratory and the offering laboratory must have scientifically validated the panel for the intended indication. FDA approval or informational FDA status alone does not establish medical necessity. At the time of request, providers must identify the performing laboratory and supply documentation demonstrating the test’s validation and intended use.

    If an unlisted code is submitted for a service that is non‑covered under this policy, the claim will be denied as not covered. For unlisted codes submitted for potentially covered services, prior authorization is recommended to reduce the risk of post‑service denial. All unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing.

    Genetic panels and multigene tests for which clinical utility has not been established are considered not medically necessary. This policy provides an extensive (but not exhaustive) illustrative list of proprietary and commercial panels identified as not medically necessary because the panels or components lack demonstrated clinical utility.

    Evidence is insufficient for many of the panels and individual panel components listed in this policy. Specifically, there is insufficient evidence that all genes/components in a given panel provide actionable diagnostic, prognostic, or management‑changing information that improves health outcomes; therefore such panels or components are considered not covered.

    This policy enumerates a broad set of molecular, genomic and panel testing procedure codes (CPT/PLA/HCPCS and other unique codes) that are addressed as non‑covered or listed for billing guidance. These include DNA methylation panels, mRNA/NGS expression panels, cytogenomic array and optical genome mapping codes, exome and multigene sequence panels, multianalyte algorithmic assays, and related procedure codes used to bill such services.

    Billing codes and coding guidance

    Non-covered panel procedure codes listedCPTNot Covered
    0321Ulisted in non-covered panel entries
    0549Ulisted in non-covered panel entries
    0012Mlisted in non-covered panel entries
    0013Mlisted in non-covered panel entries
    0363Ulisted in non-covered panel entries
    0315Ulisted in non-covered panel entries
    0288Ulisted in non-covered panel entries
    0565Ulisted in non-covered panel entries
    0332Ulisted in non-covered panel entries
    0474Ulisted in non-covered panel entries
    1–10 of 38
    1/4
    Listed CPT/PLA/unique Codes in billing guidelinesmixedNot Covered
    0012MOncology (urothelial), mRNA, gene expression profiling by RT-qPCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and XCR2), urine, algorithm reported as a risk score
    0013MOncology (urothelial), mRNA, gene expression profiling by RT-qPCR of five genes, urine, algorithm reported as a risk score for recurrent urothelial carcinoma
    0087UCardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection algorithm
    0088UTransplantation medicine (kidney allograft rejection), microarray profiling of 1494 genes, transplant biopsy tissue, probability score for rejection
    0134UHereditary pan cancer targeted mRNA sequence analysis panel (18 genes) (List separately)
    0136UATM mRNA sequence analysis (List separately)
    0175UPsychiatry genomic analysis panel, variant analysis of 15 genes
    0205UOphthalmology (age-related macular degeneration), analysis of 3 gene variants
    0258UAutoimmune (psoriasis), mRNA NGS gene expression profiling of 50-100 genes
    0271UUnexplained constitutional/heritable disorders, tissue-specific gene expression by whole-transcriptome and NGS
    1–10 of 51
    1/6
    Non-covered/Listed molecular and genomic PLA/CPT codesmixedNot Covered
    0624UDNA methylation analysis, whole blood, algorithm reported as positive or negative risk (sclerosis)
    0625UDNA methylation analysis of 5,000 sites, whole blood, algorithm reported as positive or negative risk (NASH)
    0626UDNA methylation analysis, whole blood, algorithm reported as positive or negative risk (osteoporosis)
    0627UDNA methylation analysis of >20,000 sites, whole blood, algorithm reported as positive or negative risk (Parkinson disease)
    0635UmRNA NGS gene expression profiling, reported as likelihood of response to therapy (atopic dermatitis / psychiatry references)
    81195Reported as likelihood of response to therapy
    81228Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)
    Cytogenomic and MSI testing codesCPTNot Covered
    81229Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; comparative genomic hybridization (CGH) microarray analysis
    81301Cytogenomic analysis for copy number and SNP variants, CGH microarray analysis
    81320Microsatellite instability analysis (e.g., Lynch syndrome) of markers for mismatch repair deficiency, includes comparison of neoplastic and normal tissue
    Molecular pathology, exome, oncology panels and related CPT codesCPTNot Covered
    81400Molecular pathology procedure, Level 1
    81401Molecular pathology procedure, Level 2
    81404Molecular pathology procedure, Level 5
    81405Molecular pathology procedure, Level 6
    81406Molecular pathology procedure, Level 6 (6-10 exons)
    81407Molecular pathology procedure, Level 7
    81408Molecular pathology procedure, Level 8
    81412Molecular pathology, Level 9 (analysis of >50 exons)
    81415Cardiac panel duplication/deletion analysis example reference
    81416Exome sequence analysis
    1–10 of 17
    1/2
    HCPCS and unlisted chemistry codesHCPCSNot Covered
    HCPCS S3844DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness
    HCPCS S3870Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability
    81599Unlisted chemistry procedure
    84999Unlisted chemistry procedure (paired with 81599 in listing)
    DNA methylation site counts — thresholds by code
    0617U (Neurology - dementia)DNA methylation analysis of >30,000 sites, whole blood; algorithm reported as positive/negative risk.
    0616U (Infectious disease)DNA methylation analysis reported as continuous risk scores for likelihood of bacterial/viral infection and severe illness within 7 days (whole blood); referenced with site count thresholds in billing guidelines.
    0618U (Cardiovascular - ASCVD)DNA methylation analysis of >20,000 sites, whole blood; algorithm reported as positive/negative risk.
    0619U (Psychiatry - bipolar)DNA methylation analysis of >10,000 sites, whole blood; algorithm reported as positive/negative risk.
    0620U (Pulmonary - COPD)DNA methylation analysis of >18,000 sites, whole blood; algorithm reported as positive/negative risk.

    What providers must do — documentation, prior auth, and counseling

    Prior Authorization

    Provide required clinical documentation with prior authorization

    Requests must include the clinical documentation listed below at the time of prior authorization; include the CPT/PLA codes that will be billed with the request.

    • Name of the panel test or the name of the gene(s) and/or components of the test
    • Name of laboratory that performed or is performing the test
    • Clinical notes: reason for performing test (including suspected condition), relevant signs/symptoms/test results, and family history if applicable
    • Description of how test results will impact clinical decision making
    • CPT codes billed
    Prior Authorization

    Prior authorization / listed CPT/PLA/unique codes

    Prior authorization applies to the specific non-covered panels and associated CPT/PLA/unique codes enumerated in the policy's billing and coding section; provide those codes with requests.

    Explicitly not medically necessary tests and panels

    The document explicitly lists numerous proprietary and commercial panels that are considered not medically necessary due to insufficient evidence of clinical utility. Examples include named tests such as AlloSure Kidney, CancerTYPE ID, CxBladder series, DecisionDx‑SCC, DetermaRx, MindX blood tests, Molecular Microscope (MMDx) assays, Percepta, Prospera, TruDiagnostic tests, and many Invitae and other company panels.

    Panels and codes listed in the billing and coding section are identified as lacking demonstrated clinical utility; the policy therefore treats these genetic panels and their component genes as not covered when the individual genes/components are not shown to provide actionable clinical information. Specific components and gene counts tied to certain hereditary condition panels are provided in the coding guidance.

    Numerous PLA, CPT and HCPCS codes appear in the billing section and are addressed as non‑covered or listed for this policy. These include DNA methylation analysis codes (for multiple site counts), cytogenomic and MSI testing codes (e.g., 81228, 81229, 81301, 81320), molecular pathology and exome-related CPT codes (e.g., 81400–81412, 81415–81417, 81434), multianalyte algorithm codes (e.g., 81504, 81599), and other unique PLA codes enumerated in the coding tables.

    Definitions and key terms

    Genetic panel tests — definition and summary
    DefinitionGenetic panel tests: assays that may include as few as three genes to as many as thousands of genes, enabling simultaneous testing of multiple genes and/or mutations.
    Size rangePanels range from small targeted tests (a few genes) to large panels or genome-scale tests (hundreds to thousands of genes).
    Implication of simultaneous testingSimultaneous multi-gene testing increases diagnostic efficiency but raises the likelihood of detecting variants of uncertain significance that may not change management.
    Clinical utility (per policy)
    Policy definitionClinical utility: the test provides a definitive diagnosis or risk classification (or avoids more invasive testing) AND test results will guide clinical management (predictive, diagnostic, prognostic, or therapeutic).
    Evidence requirement

    Eligibility and applicability

    No top‑level eligibility criteria are defined in this policy; eligibility requirements for specific tests are not specified in the inventory.

    There are no additional top‑level eligibility nodes captured in the inventory for this policy.

    No further eligibility placeholders were identified in the policy inventory.

    Background and rationale

    Genetic panel tests analyze multiple genes simultaneously and can improve diagnostic efficiency, but they frequently identify variants of uncertain significance (VUS) that do not alter clinical management and may lead to unnecessary procedures or harm. High‑quality evidence supports clinical utility for only selected panels; many commercially available panels and novel algorithmic tests lack peer‑reviewed evidence demonstrating improved diagnostic yield or improved health outcomes. For a panel to be considered clinically useful under this policy, testing must provide a definitive diagnosis or risk classification and avoid invasive testing when appropriate, and test results must guide clinical management.

    Policy revision history

    2026-07-01code_set_updateLatest

    Q3 2026 code set update.

    2026-04-01code_set_update

    Q2 2026 code set update.

    2026-02-01interim_update

    Interim update removing panels from the non-covered panel table.

    Policy Summary
    PayerProvidence Health Plan
    PolicyNon-Covered Genetic Panel Tests
    Policy CodePolicy 213
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateSep 1, 2026
    Key ActionProvide clinical documentation with prior authorization including panel or gene list, performing laboratory, clinical rationale, supporting findings, family history when applicable, and CPT codes billed.
    SourceLink
    On This Page
    Coverage criteria and policy scopeBilling codes and coding guidanceWhat providers must do — documentation, prior auth, and counselingExplicitly not medically necessary tests and panelsDefinitions and key termsEligibility and applicabilityBackground and rationalePolicy revision history
    0621U (Oncology - hepatocellular carcinoma)DNA methylation analysis of >5,000 sites, whole blood; algorithm reported as positive/negative risk.
    • Examples of listed codes include: 0012M, 0013M, 0087U, 0088U, 0134U, 0136U, 0175U, 0205U, 0258U, 0271U, 0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0298U, 0315U, 0319U, 0320U, 0321U, 0323U, 0332U, 0363U, 0366U, 0367U, 0420U, 0423U, 0437U, 0465U, 0474U, 0588U, 0616U, 0617U, 0618U, 0619U, 0620U, 0621U, 0622U, 0623U, 0624U, 0625U, 0626U, 0627U, 0635U, 81195, 81228, 81229, 81301, 81320
    • Inclusion on the list does not guarantee coverage; codes are provided as a courtesy.
    Prior Authorization

    Obtain prior authorization for unlisted codes (recommended)

    Prior authorization is recommended for unlisted codes submitted for potentially covered services to avoid post-service denial; unlisted codes will be reviewed at claim level.

    • All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level
    • If an unlisted code is for a potentially covered service, obtain prior authorization to reduce risk of post-service denial
    Step Therapy

    Apply condition-specific policies first

    When condition- or test-specific policies exist, those policies should be used to review single-gene or genetic panel tests before applying this non-coverage list.

    • Refer to condition-specific medical policies (cross references in the policy) for hereditary or oncologic conditions prior to using this general policy
    Note

    Engage cancer risk assessment experts for complex panels

    Involve providers with expertise in cancer risk assessment when ordering or interpreting multigene panels that include genes of uncertain clinical utility, per ASCO guidance.

    • Consider targeted gene testing based on personal/family history before ordering broad panels
    • Specialist involvement is recommended for ordering and interpretation when panels include genes not suggested by the patient's history
    Note
    Documentation Required

    Required documentation to support requests

    At the time of request, include the panel name or gene list, the performing laboratory name, and clinical notes describing the reason for testing and how results will affect care.

    • Panel name or specific gene list
    • Performing laboratory name
    • Clinical notes: suspected condition, signs/symptoms/test results, family history if applicable, and impact on clinical decision making
    Documentation Required

    Laboratory accreditation and validation documentation required

    Laboratory-performed tests must be FDA-approved and/or performed in a CLIA-accredited laboratory, and the laboratory must have scientifically validated the panel for the requested indication; FDA approval alone does not establish medical necessity.

    • Verify CLIA accreditation and scientific validation for the intended indication
    • Note that FDA approval is informational and does not by itself establish medical necessity
    Billing Rule

    Unlisted codes are subject to review at claim level

    All unlisted codes will be reviewed at claim adjudication for medical necessity, correct coding, and pricing; providers should expect claim-level review.

    • Unlisted codes for services addressed as non-covered will be denied as not covered
    • Unlisted codes for potentially covered services may be subject to prior authorization to avoid denial
    Denial Risk

    Denial risk: insufficient clinical utility

    Genetic panel testing will be denied as not medically necessary when there is insufficient evidence that the panel or its components provide proven clinical utility to guide management.

    • Both criteria A and B in the policy must be met for each gene/component to establish clinical utility
    • Panels lacking evidence that components provide actionable diagnostic, prognostic, or management-changing information are non-covered
    Denial Risk

    Denial risk when clinical utility is not demonstrated

    Tests or panels lacking evidence that genes/components provide actionable diagnostic, prognostic, or management-changing information are considered non-covered and may be denied.

    • Insufficient evidence that all genes/components provide actionable information supports non-coverage
    • Laboratory validation and indication-specific evidence are required to demonstrate clinical utility
    Denial Risk

    Unlisted code submission may be denied

    If an unlisted code is submitted for services that are non-covered by this policy, it will be denied as not covered; unlisted codes for potentially covered services may be reviewed but prior authorization is recommended to avoid post-service denial.

    • Unlisted codes for non-covered services addressed in this policy will be denied
    • Obtain prior authorization for unlisted codes for potentially covered services to reduce denial risk
    Note

    See MP316 for genetic counseling considerations

    Refer to related policy MP316 (Genetic Counseling) for counseling considerations; this policy references genetic counseling but does not itself list specific pre/post counseling mandates.

    • See MP316 for guidance on genetic counseling considerations
    Note

    Involve clinicians experienced in cancer risk assessment

    Ordering and interpretation of multigene panels that include genes of uncertain clinical utility should involve clinicians experienced in cancer risk assessment, as recommended by ASCO.

    • Specialist involvement is recommended for panels containing genes not suggested by the patient's history
    Documentation Required

    Supply clinical rationale and use condition-specific policies when available

    Provide a clinical rationale and the required documentation with any request for panel testing; when condition-specific genetic testing policies exist, use those policies first to guide ordering and review.

    • Supply clinical rationale (reason for testing, relevant findings, family history) and documentation at time of request
    • Use condition-specific policies when available before applying this general non-coverage policy
    Step Therapy

    Require experienced providers for interpretation of uncertain-significance genes

    Ordering and interpretation should involve providers experienced in cancer risk assessment when panels include genes of uncertain clinical significance; consider specialist input for interpretation and management.

    • Specialist ordering and interpretation recommended for panels that include genes of uncertain clinical utility
    • Consider targeted testing guided by personal/family history prior to broad panel testing
    Policy requires published evidence that test components produce actionable information that impacts management and improves health outcomes.
    ApplicationPanels or panel components without demonstrated clinical utility are considered not medically necessary and may be denied.
    Variant of Uncertain Significance (VUS) — definition and management
    DefinitionVariant of Uncertain Significance (VUS): a genetic alteration whose impact on protein function and clinical significance is unclear.
    Prevalence in panelsVUSs are more common in broad-panel testing because of the larger number of genes tested and limited understanding of normal variation.
    Management implicationIt is usually inappropriate to change clinical management based on a VUS alone; clinicians may overinterpret VUSs and make inappropriate recommendations.
    CLIA-accredited laboratory — definition and policy requirement
    DefinitionCLIA-accredited laboratory: a laboratory that meets Clinical Laboratory Improvement Amendments standards required for performance of high-complexity genetic testing.
    Policy requirementPanel tests must be FDA-approved and/or performed in a CLIA-accredited laboratory and scientifically validated for the requested indication.
    DocumentationRequests must identify the performing laboratory; validation of the panel for the indication is required — FDA approval alone does not establish medical necessity.
    2025-10-01annual_update

    Annual update revising the 'not medically necessary' list and Q4 2025 code set update.

    2025-07-01code_set_update

    Q3 2025 code set update; code added.

    2025-04-01code_set_update

    Q2 2025 code set update.

    2025-01-01code_set_update

    Q1 2025 code set update; updated 'not medically necessary' list.

    2024-07-01code_set_update

    Q3 2024 code set update.

    2024-01-01code_set_update

    Q1 2024 code set update.

    2023-12-01annual_update

    Annual update with revisions to the list of non-covered panels.

    2023-10-01criteria_change

    Denial criteria changed from investigational to not medically necessary and Q4 2023 code set update.

    2023-07-01annual_review

    Annual review; panels and codes already addressed by another policy were removed.

    2023-04-01code_set_update

    Q2 2023 code set update.

    2023-02-01template_conversion

    Converted to new policy template.